title: How can modeling best contribute to the assessment of secondary stroke prevention strategies?
authors.forename: David B
authors.initials: DB
authors.lastname: Matchar
authors.forename: Gregory P
authors.initials: GP
authors.lastname: Samsa
mesh_terms: D003362:Cost-Benefit Analysis; D023381:Endpoint Determination; D005343:Fibrinolytic Agents / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D008962:Models, Theoretical; D010975:Platelet Aggregation Inhibitors / Q000191:economics / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years; D020521:Stroke / Q000191:economics* / Q000517:prevention & control*
chemical_list: D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors